J.A. Killion , O.S. Jegede , D. Werb , P.J. Davidson , L.R. Smith , T. Gaines , J. Graff Zivin , M.L. Zúñiga , H.A. Pines , R.S. Garfein , S.A. Strathdee , C. Rivera Saldana , N.K. Martin
{"title":"Modeling the impact of a supervised consumption site on HIV and HCV transmission among people who inject drugs in three counties in California, USA","authors":"J.A. Killion , O.S. Jegede , D. Werb , P.J. Davidson , L.R. Smith , T. Gaines , J. Graff Zivin , M.L. Zúñiga , H.A. Pines , R.S. Garfein , S.A. Strathdee , C. Rivera Saldana , N.K. Martin","doi":"10.1016/j.drugpo.2024.104557","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Supervised consumption sites (SCS) have been shown to reduce receptive syringe sharing among people who inject drugs (PWID) in the United States and elsewhere, which can prevent HIV and hepatitis C virus (HCV) transmission. PWID are at risk of disease transmission and may benefit from SCS, however legislation has yet to support their implementation. This study aims to determine the potential impact of SCS implementation on HIV and HCV incidence among PWID in three California counties.</p></div><div><h3>Methods</h3><p>A dynamic HIV and HCV joint transmission model among PWID (sexual and injecting transmission of HIV, injecting transmission of HCV) was calibrated to epidemiological data for three counties: San Francisco, Los Angeles, and San Diego. The model incorporated HIV and HCV disease stages and HIV and HCV treatment. Based on United States data, we assumed access to SCS reduced receptive syringe sharing by a relative risk of 0.17 (95 % CI: 0.04–1.03). This model examined scaling-up SCS coverage from 0 % to 20 % of the PWID population within the respective counties and assessed its impact on HIV and HCV incidence rates after 10 years.</p></div><div><h3>Results</h3><p>By increasing SCS from 0 % to 20 % coverage among PWID, 21.8 % (95 % CI: −1.2–32.9 %) of new HIV infections and 28.3 % (95 % CI: −2.0–34.5 %) of new HCV infections among PWID in San Francisco County, 17.7 % (95 % CI: −1.0–30.8 %) of new HIV infections and 29.8 % (95 % CI: −2.1–36.1 %) of new HCV infections in Los Angeles County, and 32.1 % (95 % CI: −2.8–41.5 %) of new HIV infections and 24.3 % (95 % CI: −1.6–29.0 %) of new HCV infections in San Diego County could be prevented over ten years.</p></div><div><h3>Conclusion</h3><p>Our models suggest that SCS is an important intervention to enable HCV elimination and could help end the HIV epidemic among PWID in California. It could also have additional benefits such facilitating pathways into drug treatment programs and preventing fatal overdose.</p></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"132 ","pages":"Article 104557"},"PeriodicalIF":4.4000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S095539592400241X/pdfft?md5=bbc6661d69dc245629a6f9646bd14b33&pid=1-s2.0-S095539592400241X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Drug Policy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S095539592400241X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Supervised consumption sites (SCS) have been shown to reduce receptive syringe sharing among people who inject drugs (PWID) in the United States and elsewhere, which can prevent HIV and hepatitis C virus (HCV) transmission. PWID are at risk of disease transmission and may benefit from SCS, however legislation has yet to support their implementation. This study aims to determine the potential impact of SCS implementation on HIV and HCV incidence among PWID in three California counties.
Methods
A dynamic HIV and HCV joint transmission model among PWID (sexual and injecting transmission of HIV, injecting transmission of HCV) was calibrated to epidemiological data for three counties: San Francisco, Los Angeles, and San Diego. The model incorporated HIV and HCV disease stages and HIV and HCV treatment. Based on United States data, we assumed access to SCS reduced receptive syringe sharing by a relative risk of 0.17 (95 % CI: 0.04–1.03). This model examined scaling-up SCS coverage from 0 % to 20 % of the PWID population within the respective counties and assessed its impact on HIV and HCV incidence rates after 10 years.
Results
By increasing SCS from 0 % to 20 % coverage among PWID, 21.8 % (95 % CI: −1.2–32.9 %) of new HIV infections and 28.3 % (95 % CI: −2.0–34.5 %) of new HCV infections among PWID in San Francisco County, 17.7 % (95 % CI: −1.0–30.8 %) of new HIV infections and 29.8 % (95 % CI: −2.1–36.1 %) of new HCV infections in Los Angeles County, and 32.1 % (95 % CI: −2.8–41.5 %) of new HIV infections and 24.3 % (95 % CI: −1.6–29.0 %) of new HCV infections in San Diego County could be prevented over ten years.
Conclusion
Our models suggest that SCS is an important intervention to enable HCV elimination and could help end the HIV epidemic among PWID in California. It could also have additional benefits such facilitating pathways into drug treatment programs and preventing fatal overdose.
期刊介绍:
The International Journal of Drug Policy provides a forum for the dissemination of current research, reviews, debate, and critical analysis on drug use and drug policy in a global context. It seeks to publish material on the social, political, legal, and health contexts of psychoactive substance use, both licit and illicit. The journal is particularly concerned to explore the effects of drug policy and practice on drug-using behaviour and its health and social consequences. It is the policy of the journal to represent a wide range of material on drug-related matters from around the world.